Trevi Therapeutics, Inc. (TRVI)

NASDAQ: TRVI · IEX Real-Time Price · USD
1.75
-0.04 (-2.23%)
At close: Sep 27, 2022 4:00 PM
1.74
-0.01 (-0.86%)
After-hours: Sep 27, 2022 4:06 PM EDT
-2.23%
Market Cap 77.12M
Revenue (ttm) n/a
Net Income (ttm) -31.16M
Shares Out 44.07M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 224,711
Open 1.88
Previous Close 1.79
Day's Range 1.73 - 1.88
52-Week Range 0.46 - 4.68
Beta 0.20
Analysts Buy
Price Target 10.20 (+482.9%)
Earnings Date Nov 8, 2022

About TRVI

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in ... [Read more...]

Industry Pharmaceuticals
IPO Date May 7, 2019
Employees 23
Stock Exchange NASDAQ
Ticker Symbol TRVI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for TRVI stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 482.86% from the latest price.

Price Target
$10.2
(482.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering

NEW HAVEN, Conn. , Sept. 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral nalbuphine ER)...

4 days ago - PRNewsWire

Trevi Therapeutics Announces Proposed Public Offering

NEW HAVEN, Conn. , Sept. 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral nalbuphine ER)...

5 days ago - PRNewsWire

Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatm...

Data from full set of subjects was statistically significant for the primary efficacy endpoint of daytime cough frequency reduction (p

1 week ago - PRNewsWire

Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Presentation will be held on Monday, September 12, 2022, from 10:30 a.m. to 11:00 a.m.

2 weeks ago - PRNewsWire

Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022

The event will feature presentations from experts Dr. Peter Dicpinigaitis, MD, and Dr. Brian Kim, MD, MTR Virtual event to be held on Monday, September 19 th from 10 AM – 12:30 PM ET NEW HAVEN, Conn. , ...

4 weeks ago - PRNewsWire

Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferenc...

Late-breaker abstract accepted for oral presentation on the interim analysis of cough in patients with idiopathic pulmonary fibrosis (IPF) at the upcoming European Respiratory Society International Cong...

1 month ago - PRNewsWire

Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day Pod...

Phoenix, Arizona--(Newsfile Corp. - August 22, 2022) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"), a clinical-stage biopharmaceutical company focused on the d...

1 month ago - Newsfile Corp

Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Reported positive results from the Phase 2b/3 PRISM trial of Haduvio™ in the treatment of Prurigo Nodularis Completed a $55 million private placement Data from the full set of subjects in the completed ...

1 month ago - PRNewsWire

Trevi Therapeutics to Present at Upcoming August Conferences

NEW HAVEN, Conn. , Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) fo...

1 month ago - PRNewsWire

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

1 month ago - PRNewsWire

5 Penny Stocks to Buy on the Dip

These penny stocks can be of significant value in the long run due to their growth prospects and innovation. The post 5 Penny Stocks to Buy on the Dip appeared first on InvestorPlace.

Other symbols: DSXELTKPANLRMO
2 months ago - InvestorPlace

Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi Therapeutics

NEW YORK, NY / ACCESSWIRE / July 14, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a ...

2 months ago - Accesswire

Trevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS)

NEW HAVEN, Conn. , July 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) fo...

2 months ago - PRNewsWire

Why Did Needham Lift Price Target For Trevi?

Yesterday Trevi Therapeutics Inc's (NASDAQ: TRVI) Phase 2b/3 trial (PRISM) evaluating Haduvio (nalbuphine ER) for prurigo nodularis (PN) successfully met the key primary and secondary endpoints.  Needha...

2 months ago - Benzinga

Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical Data

Trevi Therapeutics (TRVI) stock is flying higher Wednesday following the release of positive trial data for its skin disease treatment! The post Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical...

2 months ago - InvestorPlace

Trevi Therapeutics (TRVI) Stock Spikes 20% on Positive Clinical Data

Trevi Therapeutics (TRVI) stock is flying higher Wednesday following the release of positive trial data for its skin disease treatment. The post Trevi Therapeutics (TRVI) Stock Spikes 20% on Positive Cl...

2 months ago - InvestorPlace

Why Trevi Therapeutics Shares Trading Higher Today?

Trevi Therapeutics Inc (NASDAQ: TRVI) has announced positive results from its Phase 2b/3 PRISM trial of Haduvio in treating prurigo nodularis, a chronic disease characterized by severe pruritus and the ...

2 months ago - Benzinga

Trevi's stock gains 38% after announcing positive data for skin-disease drug

Shares of Trevi Therapeutics Inc. TRVI, +1.00% jumped 38.1% in premarket trading on Wednesday after the company said its experimental treatment for prurigo nodularis, a type of inflammatory skin disease...

2 months ago - Market Watch

Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodul...

Haduvio (oral nalbuphine ER) demonstrated statistically significant results on the primary efficacy endpoint as measured  by a 4-point reduction in the Worst Itch – Numerical Rating Scale (WI-NRS) (p=0....

2 months ago - PRNewsWire

Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention

NEW HAVEN, Conn. , June 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pru...

3 months ago - PRNewsWire

Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update

Accelerated planning for next phase of development of Haduvio for the treatment of chronic cough in IPF based on results from statistically significant interim analysis of Phase 2 CANAL Trial Completed ...

4 months ago - PRNewsWire

Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022

Conference Call and Webcast to be Held at 4:30 p.m. EDT NEW HAVEN, Conn.

4 months ago - PRNewsWire

Trevi Therapeutics to Present at Upcoming May Meetings

NEW HAVEN, Conn. , May 3, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for prur...

4 months ago - PRNewsWire

Are You Looking for a Top Momentum Pick? Why Trevi Therapeutics, Inc. (TRVI) is a Great Choice

Does Trevi Therapeutics, Inc. (TRVI) have what it takes to be a top stock pick for momentum investors? Let's find out.

5 months ago - Zacks Investment Research

Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

UPDATE: Fireside chat will be held on Tuesday, April 12, 2022, from 10:15 a.m. to 10:55 a.m.

5 months ago - PRNewsWire